➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Boehringer Ingelheim
AstraZeneca
Harvard Business School
Mallinckrodt

Last Updated: August 2, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MEKINIST

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for MEKINIST

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01438554 ↗ Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma Active, not recruiting GlaxoSmithKline Phase 1 2011-10-01 The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study.
NCT01438554 ↗ Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma Active, not recruiting National Comprehensive Cancer Network Phase 1 2011-10-01 The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study.
NCT01438554 ↗ Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma Active, not recruiting Sidney Kimmel Comprehensive Cancer Center Phase 1 2011-10-01 The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study.
NCT01553851 ↗ GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer Completed National Comprehensive Cancer Network Phase 2 2013-02-01 This phase II trial studies how trametinib effects tumor cells in patients with oral cavity squamous cell carcinoma that can be removed by surgery. Trametinib may shrink the tumor by blocking an enzyme pathway needed for cell growth.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for MEKINIST

Condition Name

Condition Name for MEKINIST
Intervention Trials
Melanoma 12
Stage IV Skin Melanoma 6
Stage IIIC Skin Melanoma 6
Recurrent Melanoma 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for MEKINIST
Intervention Trials
Melanoma 24
Carcinoma 13
Lung Neoplasms 7
Carcinoma, Non-Small-Cell Lung 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for MEKINIST

Trials by Country

Trials by Country for MEKINIST
Location Trials
United States 353
Canada 7
United Kingdom 6
Germany 5
France 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for MEKINIST
Location Trials
Texas 18
California 16
Ohio 15
Massachusetts 14
New York 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for MEKINIST

Clinical Trial Phase

Clinical Trial Phase for MEKINIST
Clinical Trial Phase Trials
Phase 4 1
Phase 3 2
Phase 2/Phase 3 1
[disabled in preview] 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for MEKINIST
Clinical Trial Phase Trials
Recruiting 40
Not yet recruiting 18
Active, not recruiting 7
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for MEKINIST

Sponsor Name

Sponsor Name for MEKINIST
Sponsor Trials
National Cancer Institute (NCI) 31
Novartis Pharmaceuticals 9
Novartis 7
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for MEKINIST
Sponsor Trials
Other 66
Industry 34
NIH 31
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Johnson and Johnson
Colorcon
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.